Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Ncgc00166281-01
2. Dsstox_cid_24280
3. Dsstox_rid_80140
4. Dsstox_gsid_44280
5. 130-95-0
6. Cas-130-95-0
7. Sr-01000075160
8. Quinine (ban)
9. Kinder Quinina (tn)
10. Lopac0_001029
11. Mls001304041
12. Chembl387326
13. Schembl12310700
14. Hms2233l08
15. Tox21_112389
16. Bdbm50411276
17. Akos015955637
18. Tox21_112389_1
19. Ncgc00274071-01
20. Smr000718748
21. C06526
22. D08460
23. Sr-01000075160-1
24. Sr-01000075160-12
25. (alphar,2s)-alpha-(6-methoxy-4-quinolyl)-5beta-vinyl-2alpha-quinuclidinemethanol
Molecular Weight | 324.4 g/mol |
---|---|
Molecular Formula | C20H24N2O2 |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 4 |
Exact Mass | 324.183778013 g/mol |
Monoisotopic Mass | 324.183778013 g/mol |
Topological Polar Surface Area | 45.6 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 457 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Quinine sulfate |
Drug Label | Quinine sulfate is a cinchona alkaloid chemically described as cinchonan-9-ol, 6'-methoxy-, (8, 9R)-, sulfate (2:1) (salt), dihydrate with a molecular formula of (C20H24N2O2)2H2SO42H2O and a molecular weight of 782.96.The structural formula o... |
Active Ingredient | Quinine sulfate |
Dosage Form | Capsule |
Route | Oral |
Strength | 324mg |
Market Status | Prescription |
Company | Mylan Pharms; Teva Pharms |
2 of 2 | |
---|---|
Drug Name | Quinine sulfate |
Drug Label | Quinine sulfate is a cinchona alkaloid chemically described as cinchonan-9-ol, 6'-methoxy-, (8, 9R)-, sulfate (2:1) (salt), dihydrate with a molecular formula of (C20H24N2O2)2H2SO42H2O and a molecular weight of 782.96.The structural formula o... |
Active Ingredient | Quinine sulfate |
Dosage Form | Capsule |
Route | Oral |
Strength | 324mg |
Market Status | Prescription |
Company | Mylan Pharms; Teva Pharms |
Analgesics, Non-Narcotic; Antimalarials; Muscle Relaxants, Central
National Library of Medicine's Medical Subject Headings. Quinine. Online file (MeSH, 2014). Available from, as of August 28, 2014: https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html
Qualaquin (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented. /Included in US product label/
NIH; DailyMed. Current Medication Information for Qualaquin (Quinine Sulfate) Capsule (Revised: April 2013). Available from, as of November 20, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f66fba7-4026-4504-918d-4c88f2835cc0
Oral quinine sulfate is used in conjunction with IV or oral clindamycin for the treatment of babesiosis caused by Babesia microti. /NOT included in US product label/
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
Although quinine sulfate is not approved by the FDA for the treatment of severe or complicated malaria, the CDC states that oral quinine sulfate can be used in conjunction with doxycycline, tetracycline, or clindamycin for follow-up treatment after an appropriate initial parenteral regimen.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
For more Therapeutic Uses (Complete) data for QUININE (8 total), please visit the HSDB record page.
/BOXED WARNING/ WARNING: Qualaquin use for the treatment or prevention of nocturnal leg cramps may result in serious and life-threatening hematologic reactions, including thrombocytopenia and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP). Chronic renal impairment associated with the development of TTP has been reported. The risk associated with Qualaquin use in the absence of evidence of its effectiveness in the treatment or prevention of nocturnal leg cramps outweighs any potential benefit.
NIH; DailyMed. Current Medication Information for Qualaquin (Quinine Sulfate) Capsule (Revised: April 2013). Available from, as of November 20, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f66fba7-4026-4504-918d-4c88f2835cc0
Serious hypersensitivity reactions, including anaphylactic shock, anaphylactoid reactions, urticaria, serious skin rashes (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), angioedema, facial edema, bronchospasm, and pruritus, have been reported with quinine. In addition, thrombocytopenia, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), immune thrombocytopenic purpura, blackwater fever, disseminated intravascular coagulation, leukopenia, neutropenia, granulomatous hepatitis, and acute interstitial nephritis have been reported and may also be due to hypersensitivity reactions to the drug.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
Potentially fatal cardiac arrhythmias, including torsades de pointes and ventricular fibrillation, have been reported rarely during quinine therapy. At least 1 case of fatal ventricular arrhythmia has been reported in a geriatric patient with preexisting prolonged QT interval treated with IV quinine sulfate for Plasmodium falciparum malaria.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
Serious, life-threatening, and sometimes fatal hematologic reactions, including thrombocytopenia and thrombocytopenia, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), have been reported in patients receiving quinine, especially patients using the drug for unlabeled indications (prevention or treatment of leg cramps or restless leg syndrome). Subsequent development of chronic renal impairment has occurred in patients with quinine-associated TTP.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
For more Drug Warnings (Complete) data for QUININE (37 total), please visit the HSDB record page.
The average fatal dose for an adult is about 8 g although deaths have been reported from as little as 1.5 g in an adult and 900 mg in a child.
IPCS; UK Poison Information Documents (UKPID) for Quinine (Last updated March 1996). Available from, as of November 20, 2014: https://www.inchem.org/pages/ukpids.html
A lethal dose of quinine has not been clearly defined, but fatalities have been reported after the ingestion of 2 to 8 grams in adults.
NIH; DailyMed. Current Medication Information for Qualaquin (Quinine Sulfate) Capsule (Revised: April 2013). Available from, as of November 20, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f66fba7-4026-4504-918d-4c88f2835cc0
Following oral administration of a single 600-mg dose of quinine sulfate in healthy adults, the mean plasma clearance was 0.08-0.47 L/hour per kg (median: 0.17 L/hour per kg) and the mean plasma elimination half-life was 9.7-12.5 hours. Following oral administration of 10 mg/kg of quinine sulfate in patients with uncomplicated malaria, mean total clearance of quinine was decreased (approximately 0.09 L/hour per kg) during the acute phase of the infection and increased (approximately 0.16 L/hour per kg) during the recovery or convalescent phase.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
Following oral administration of a single 600-mg dose of quinine sulfate in geriatric and younger adults, the mean clearance of the drug was decreased (0.06 versus 0.08 L/hour per kg) and the mean elimination half-life was significantly increased (18.4 versus 10.5 hours) in geriatric adults compared with younger adults. Although renal clearance of quinine was similar in geriatric and younger adults, geriatric adults excreted a larger proportion of the dose in urine as unchanged drug compared with younger adults (16.6 versus 11.2%). The steady-state pharmacokinetics after a quinine sulfate dosage of 648 mg 3 times daily for 7 days were similar in healthy geriatric adults 65-78 years of age and healthy younger adults 20-39 years of age; however, the mean elimination half-life was 24 hours in the geriatric individuals compared with 20 hours in the younger adults.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
Following oral administration of a single dose of 10 mg/kg of quinine sulfate in healthy children or pediatric patients 1.5-12 years of age with uncomplicated Plasmodium falciparum malaria, the mean total clearance (0.06 versus 0.3 L/hour per kg) is reduced and the plasma elimination half-life increased (12.1 versus 3.21 hours) in pediatric patients with malaria as compared to that observed in healthy children.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
In 15 patients with uncomplicated malaria who received a 10 mg/kg oral dose of quinine sulfate, the mean total clearance of quinine was slower (approximately 0.09 L/hr/kg) during the acute phase of the infection, and faster (approximately 0.16 L/hr/kg) during the recovery or convalescent phase.
NIH; DailyMed. Current Medication Information for Qualaquin (Quinine Sulfate) Capsule (Revised: April 2013). Available from, as of November 20, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f66fba7-4026-4504-918d-4c88f2835cc0
For more Absorption, Distribution and Excretion (Complete) data for QUININE (19 total), please visit the HSDB record page.
In vitro studies using human liver microsomes and recombinant P450 enzymes have shown that quinine is metabolized mainly by CYP3A4. Depending on the in vitro experimental conditions, other enzymes, including CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were shown to have some role in the metabolism of quinine.
NIH; DailyMed. Current Medication Information for Qualaquin (Quinine Sulfate) Capsule (Revised: April 2013). Available from, as of November 20, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f66fba7-4026-4504-918d-4c88f2835cc0
Quinine is metabolized almost exclusively via hepatic oxidative cytochrome P450 (CYP) pathways, resulting in four primary metabolites, 3-hydroxyquinine, 2'-quinone, O-desmethylquinine, and 10,11-dihydroxydihydroquinine. Six secondary metabolites result from further biotransformation of the primary metabolites. The major metabolite, 3-hydroxyquinine, is less active than the parent drug.
NIH; DailyMed. Current Medication Information for Qualaquin (Quinine Sulfate) Capsule (Revised: April 2013). Available from, as of November 20, 2014: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1f66fba7-4026-4504-918d-4c88f2835cc0
Compared with administration of quinine alone, administration of a single 600-mg dose of quinine sulfate in healthy individuals who were receiving ritonavir (200 mg every 12 hours) resulted in an increased quinine mean elimination half-life (11.2 hours versus 13.4 hours).
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
The plasma elimination half-life of quinine reportedly averages 8-21 hours in adults with malaria and 7-12 hours in healthy or convalescing adults.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
The steady-state pharmacokinetics after a quinine sulfate dosage of 648 mg 3 times daily for 7 days were similar in healthy geriatric adults 65-78 years of age and healthy younger adults 20-39 years of age; however, the mean elimination half-life was 24 hours in the geriatric individuals compared with 20 hours in the younger adults.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
In children 1-12 years of age, the plasma elimination half-life of quinine reportedly averages 11-12 hours in those with malaria and 6 hours in those convalescing from the disease.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
At toxic levels elimination half life is reported to be 26.5 + or - 5.8 hrs.
IPCS; UK Poison Information Documents (UKPID) for Quinine (Last updated March 1996). Available from, as of November 20, 2014: https://www.inchem.org/pages/ukpids.html
Quinine has a local anesthetic action and analgesic, antipyretic, and oxytocic effects. Quinine also has cardiovascular effects similar to those of quinidine.
American Society of Health-System Pharmacists 2014; Drug Information 2014. Bethesda, MD. 2014
Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24063
Submission : 2010-07-19
Status : Active
Type : II
Certificate Number : R0-CEP 2005-117 - Rev 01
Issue Date : 2009-07-02
Type : Chemical
Substance Number : 19
Status : Withdrawn by EDQM F...
Date of Issue : 2021-12-16
Valid Till : 2024-05-20
Written Confirmation Number : WC-0303n
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-24
Pay. Date : 2013-06-14
DMF Number : 17086
Submission : 2004-01-05
Status : Active
Type : II
NDC Package Code : 12065-1706
Start Marketing Date : 2001-05-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9462
Submission : 1991-12-13
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19905
Submission : 2006-10-24
Status : Inactive
Type : II
Certificate Number : CEP 2024-412 - Rev 00
Issue Date : 2025-04-07
Type : Chemical
Substance Number : 19
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23415
Submission : 2009-12-15
Status : Inactive
Type : II
Certificate Number : R0-CEP 2009-387 - Rev 00
Issue Date : 2011-04-06
Type : Chemical
Substance Number : 19
Status : Withdrawn by EDQM F...
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31629
Submission : 2017-04-20
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20951
Submission : 2007-09-03
Status : Inactive
Type : II
Certificate Number : R1-CEP 2014-170 - Rev 00
Issue Date : 2020-07-20
Type : Chemical
Substance Number : 19
Status : Valid
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Italy
Brand Name : Quinine Sulphate
Dosage Form :
Dosage Strength : 20 Cpr 250 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Quinine Sulphate
Dosage Form :
Dosage Strength : 20 Cpr Riv 250 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Quinine Sulphate
Dosage Form :
Dosage Strength : 20 Cpr 250 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Dosage Form : Capsule
Grade : Not Available
Application : Solubilizers
Excipient Details : Solubilizing matrix, crystallization inhibitor & stabilizer in injectables and ophthalmic products
Dosage Form : Capsule
Grade : Not Available
Application : Solubilizers
Excipient Details : Solubilizing matrix, crystallization inhibitor & stabilizer in injectables and ophthalmic products
Pharmacopoeia Ref : Ph. Eur., USP: Povidone; JPE: ...
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Controlled & Modified Release
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Dosage Form : Tablet
Grade : Not Available
Application : Solubilizers
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Capsule
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Tablet binding, thickener, stabilizers of suspensions, reduces sedimentation, crystallization inhibition.
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : For non-erodible matrices using direct compression, Controlled release matrix. Matrix former in transdermal patches and topical films.
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP-JPE: 80 %...
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Tablet
Grade : Not Available
Application : Granulation
Excipient Details : Wetting agent, reduces disintegration time, Ionic solubilizer, high HLB anionic emulsifier for semi-solids and foams.
Pharmacopoeia Ref : Ph. Eur.: Sodium Laurilsulfate...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Dosage Form : Tablet
Grade : Not Available
Application : Film Formers & Plasticizers
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
Dosage Form : Softgel Capsule
Grade : Not Available
Application : Thickeners and Stabilizers
Excipient Details : Structure-building consistency factor with dry feel, forms crystalline barrier on skin
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP: Stearic ...
Technical Specs : Not Available
Ingredient(s) : Stearic Acid
Dosage Form : Granule / Pellet
Grade : Not Available
Application : Direct Compression
Excipient Details : Ready-to-use direct compression solution for tablets.
Excipients by Applications
Dosage Form : Tablet
Grade : Oral
Category : Granulation, Lubricants & Glidants, Surfactant & Foaming Agents
Dosage Form : Capsule, Tablet, Topical Film, Transdermal Patch
Grade : Not Available
Category : Controlled & Modified Release, Direct Compression, Granulation
Application : Controlled & Modified Release, Direct Compression, Granulation
Excipient Details : For non-erodible matrices using direct compression, Controlled release matrix. Matrix former in transdermal patches and topical films.
Pharmacopoeia Ref : Ph. Eur., USP-NF, JP-JPE: 80 %...
Technical Specs : Not Available
Ingredient(s) : Lauryl Sulfate
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Granulation
Application : Direct Compression, Fillers, Diluents & Binders, Granulation
Excipient Details : AceCel is suitable for majority of the directly compressible actives, combines good flow and high compressibility.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Disintegrants & Superdisintegrants, Granulation
Dosage Form : Tablet
Grade : Oral
Category : Direct Compression, Fillers, Diluents & Binders, Granulation
Application : Direct Compression, Fillers, Diluents & Binders, Granulation
Excipient Details : HiCel acts as a strong dry binder. It facilitates low tablet friability & promotes rapid tablet disintegration.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose
Application : Fillers, Diluents & Binders, Granulation
Excipient Details : Fully Pregel Starch Corn is used as a binder in wet granulation in the manufacturing of tablets.
Pharmacopoeia Ref : USP/NF, Ph. Eur., Ch. P.
Technical Specs : NA
Ingredient(s) : Corn Starch, Pregelatinized
Application : Fillers, Diluents & Binders, Granulation
Application : Granulation
Excipient Details : Wetting agent, reduces disintegration time, Ionic solubilizer, high HLB anionic emulsifier for semi-solids and foams.
Pharmacopoeia Ref : Ph. Eur.: Sodium Laurilsulfate...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Grade : Not Available
Category : Direct Compression, Granulation, Lubricants & Glidants
Brand Name : Kolliphor SLS Fine
Application : Direct Compression, Granulation, Lubricants & Glidants
Excipient Details : Wetting agent, reducing disintegration time, direct compression, Hydrophilic lubricant, effervescent tablets.
Pharmacopoeia Ref : Ph. Eur.: Sodium Laurilsulfate...
Technical Specs : Not Available
Ingredient(s) : Sodium Lauryl Sulfate
Application : Direct Compression, Granulation
Excipient Details : HiCellac is used in direct compression & dry granulation suitable for low dose formulations where API content uniformity is critical.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Lactose Monohydrate
Dosage Form : Cream / Lotion / Ointment, Gel, Solution
Grade : Oral, Topical
Category : Emulsifying Agents, Solubilizers, Topical
Application : Emulsifying Agents, Solubilizers, Topical
Excipient Details : Hydrosol 50 is used as a solubilizer and emulsifying agent in oral and topical liquid and semi-solid dosage forms.
Pharmacopoeia Ref : USP/NF
Technical Specs : N/A
Ingredient(s) : Polyoxyl 40 Hydrogenated Castor Oil
Brand Name : Microlex® PVD K30
Application : Solubilizers
Pharmacopoeia Ref : Monograph- USP/NF, JP/JPE
Technical Specs : Also Available as Microlex® PVD K90.
Ingredient(s) : Povidone
Dosage Form : Capsule, Emulsion, Softgel Capsule, Solution, Tablet, Topical Film
Grade : Not Available
Category : Film Formers & Plasticizers, Solubilizers, Topical
Application : Film Formers & Plasticizers, Solubilizers, Topical
Excipient Details : Liquid plasticizer with high ADI, hydrophilic solvent & humectant in emulsions, skin penetration enhancer in topical formulaitons.
Pharmacopoeia Ref : Ph. Eur., JP, FCC, USP
Technical Specs : Not Available
Ingredient(s) : Propylene Glycol
Grade : Oral
Category : Coating Systems & Additives, Fillers, Diluents & Binders, Film Formers & Plasticizers, Solubilizers, Thickeners and Stabilizers
Application : Coating Systems & Additives, Fillers, Diluents & Binders, Film Formers & Plasticizers, Solubilizers, Thickeners and Stabilizers
Pharmacopoeia Ref : USP-NF, EP, BP, IP, JP, FCC
Technical Specs : PVP K-K-30/ K-17/ K19/ K25/ K90
Ingredient(s) : Povidone
Dosage Form : Capsule, Tablet, Transdermal Patch, Transdermal patches
Grade : Not Available
Category : Controlled & Modified Release, Solubilizers
Application : Controlled & Modified Release, Solubilizers
Excipient Details : Solubilization, dispersion, crystallization inhibition, instant release matrices & spray drying
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Capsule, Granule / Pellet, Softgel Capsule, Suspension, Tablet
Grade : Not Available
Category : Fillers, Diluents & Binders, Granulation, Solubilizers
Application : Fillers, Diluents & Binders, Granulation, Solubilizers
Excipient Details : Tablet binding, thickener, stabilizers of suspensions, reduces sedimentation, crystallization inhibition.
Pharmacopoeia Ref : Ph. Eur., USP, JP: Povidone
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Capsule, Emulsion, Softgel Capsule, Solution, Tablet, Transdermal patches
Grade : Not Available
Category : Parenteral, Solubilizers
Application : Parenteral, Solubilizers
Excipient Details : Solubilizing matrix, crystallization inhibitor & stabilizer in injectables and ophthalmic products
Pharmacopoeia Ref : Ph. Eur., USP: Povidone; JPE: ...
Technical Specs : Not Available
Ingredient(s) : Povidone
Dosage Form : Capsule, Emulsion, Granule / Pellet, Softgel Capsule, Solution, Tablet, Transdermal patches
Grade : Not Available
Category : Parenteral, Solubilizers
Application : Parenteral, Solubilizers
Excipient Details : Solubilizing matrix, crystallization inhibitor & stabilizer in injectables and ophthalmic products
Global Sales Information
Market Place
Reply
20 May 2022
Reply
31 Oct 2017
Reply
08 Jul 2017
ABOUT THIS PAGE
68
PharmaCompass offers a list of Quinine Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Quinine Sulfate manufacturer or Quinine Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Quinine Sulfate manufacturer or Quinine Sulfate supplier.
PharmaCompass also assists you with knowing the Quinine Sulfate API Price utilized in the formulation of products. Quinine Sulfate API Price is not always fixed or binding as the Quinine Sulfate Price is obtained through a variety of data sources. The Quinine Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A QUALAQUIN manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of QUALAQUIN, including repackagers and relabelers. The FDA regulates QUALAQUIN manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. QUALAQUIN API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of QUALAQUIN manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A QUALAQUIN supplier is an individual or a company that provides QUALAQUIN active pharmaceutical ingredient (API) or QUALAQUIN finished formulations upon request. The QUALAQUIN suppliers may include QUALAQUIN API manufacturers, exporters, distributors and traders.
click here to find a list of QUALAQUIN suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A QUALAQUIN DMF (Drug Master File) is a document detailing the whole manufacturing process of QUALAQUIN active pharmaceutical ingredient (API) in detail. Different forms of QUALAQUIN DMFs exist exist since differing nations have different regulations, such as QUALAQUIN USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A QUALAQUIN DMF submitted to regulatory agencies in the US is known as a USDMF. QUALAQUIN USDMF includes data on QUALAQUIN's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The QUALAQUIN USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of QUALAQUIN suppliers with USDMF on PharmaCompass.
A QUALAQUIN CEP of the European Pharmacopoeia monograph is often referred to as a QUALAQUIN Certificate of Suitability (COS). The purpose of a QUALAQUIN CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of QUALAQUIN EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of QUALAQUIN to their clients by showing that a QUALAQUIN CEP has been issued for it. The manufacturer submits a QUALAQUIN CEP (COS) as part of the market authorization procedure, and it takes on the role of a QUALAQUIN CEP holder for the record. Additionally, the data presented in the QUALAQUIN CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the QUALAQUIN DMF.
A QUALAQUIN CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. QUALAQUIN CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of QUALAQUIN suppliers with CEP (COS) on PharmaCompass.
A QUALAQUIN written confirmation (QUALAQUIN WC) is an official document issued by a regulatory agency to a QUALAQUIN manufacturer, verifying that the manufacturing facility of a QUALAQUIN active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting QUALAQUIN APIs or QUALAQUIN finished pharmaceutical products to another nation, regulatory agencies frequently require a QUALAQUIN WC (written confirmation) as part of the regulatory process.
click here to find a list of QUALAQUIN suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing QUALAQUIN as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for QUALAQUIN API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture QUALAQUIN as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain QUALAQUIN and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a QUALAQUIN NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of QUALAQUIN suppliers with NDC on PharmaCompass.
QUALAQUIN Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of QUALAQUIN GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right QUALAQUIN GMP manufacturer or QUALAQUIN GMP API supplier for your needs.
A QUALAQUIN CoA (Certificate of Analysis) is a formal document that attests to QUALAQUIN's compliance with QUALAQUIN specifications and serves as a tool for batch-level quality control.
QUALAQUIN CoA mostly includes findings from lab analyses of a specific batch. For each QUALAQUIN CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
QUALAQUIN may be tested according to a variety of international standards, such as European Pharmacopoeia (QUALAQUIN EP), QUALAQUIN JP (Japanese Pharmacopeia) and the US Pharmacopoeia (QUALAQUIN USP).